BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
Researchers have discovered a protein system that helps explain why some colorectal cancer patients don’t respond to ...
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational study build on the strength of the data for amivantamab in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback